Comparative effectiveness of triple versus dual inhaled therapy (ICS/LABA or LABA/LAMA) for chronic obstructive pulmonary disease: a systematic review and network meta-analysis
Weimian Hu, Qinglin Li · 2026
Read Comparative effectiveness of triple versus dual inhaled therapy (ICS/LABA or LABA/LAMA) for chronic obstructive pulmonary disease: a systematic review and network meta-analysis by Weimian Hu, Qinglin Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13450538.txt.
Description
Weimian Hu and Qinglin Li compared triple versus dual inhaler therapy for chronic obstructive pulmonary disease in a 2026 network meta-analysis. Triple therapy adds a third drug to two-drug inhalers, promising modest gains but raising safety worries, especially pneumonia. Whether the extra drug earns its place over either dual combination was uncertain.
The team searched six databases through July 2023 for randomized trials of triple therapy against ICS/LABA or LABA/LAMA dual therapy. Seven trials with 9,968 participants were synthesized, covering flare-ups, lung function, quality of life, breathlessness, and pneumonia. Ranking methods placed treatments in order for each outcome. Prescribers gain a balanced view of added benefit versus added harm.
Catalog record
| CREATOR | Weimian Hu, Qinglin Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |